

REMARKS


Claims 1-5 are pending in the above-referenced application. The Examiner has issued a restriction requirement that requires Applicants to elect one of groups I-II as defined in the Office Action mailed on February 10, 2006. Accordingly, Applicants hereby elect Group I which encompasses claim 1. The Examiner has also required that the Applicants provisionally elect a single species within the genus of compounds listed in claim 1. Accordingly, Applicants hereby provisionally elect the compound 3-(3-tert-butyl-5-iodophenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridi- n-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid. Claim 1 reads on this elected species.

CONCLUSION

If any fees are due in connection with this response, including the fee for any required extension of time (for which Applicants hereby petition), please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: February 27, 2006


Matthew J. Pugmire
Attorney for Applicants
Registration No. 54,723

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 638-6349
Fax: (858) 678-8233